Monday, April 2nd, 2018
RPDC will establish and operate “The Saudi Vaccine and Biopharmaceutical Center ” which is a result of the partnership between KACST and KAUST that aims to localize the production of vaccine and biopharmaceutical product’s. RPDC Research Product Development Company is a Subsidiary of The Saudi Technology Development and Investment Company (TAQNIA)
The center will be built to suit the R&D needs by providing efficient laboratories to ensure that the final products meet the global standards and practices to be licensed by the General Authority for Food and Drug Administration in the Kingdom of Saudi Arabia. It’s worth mentioning that the center will be located at KAUST.